0

Viral Hepatitis Collection
 1-20 of 149 Articles
Reviews |  21 June 2016 ONLINE FIRST
Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysisHepatitis C Core Antigen Testing
J. Morgan Freiman, MD; Trang M. Tran, BA; Samuel G. Schumacher, MSc, PhD; et al.
Ann Intern Med. Published online 21 June 2016 doi:10.7326/M16-0065
Ideas and Opinions |  12 April 2016 ONLINE FIRST
What Stands in the Way of Making Hepatitis B and C Rare Diseases in the United States?Hepatitis B and C Could Be Rare
Gillian J. Buckley, PhD, MPH; Brian L. Strom, MD, MPH
Ann Intern Med. Published online 12 April 2016 doi:10.7326/M16-0772
Original Research |  19 January 2016
Prevention of Hepatitis C by Screening and Treatment in U.S. PrisonsPrevention of Hepatitis C in U.S. Prisons
Tianhua He, MD; Kan Li, MS; Mark S. Roberts, MD, MPP; et al.
Ann Intern Med. 2016;164(2):84-92. doi:10.7326/M15-0617
Editorials |  5 January 2016
Evaluating Hepatitis B Virus Reactivation During Solid Tumor Chemotherapy: Evidence to Guide Pretreatment Hepatitis B Screening and ProphylaxisEvidence to Guide Pretreatment Hepatitis B Screening and Prophylaxis
Vincent Lo Re, III, MD, MSCE; Mindy Schuster, MD, MSCE
Ann Intern Med. 2016;164(1):64-65. doi:10.7326/M15-2722
Reviews |  5 January 2016
Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysisHBV Reactivation in Solid Tumors
Sonali Paul, MD, MS; Akriti Saxena, MD; Norma Terrin, PhD; et al.
Ann Intern Med. 2016;164(1):30-40. doi:10.7326/M15-1121
Original Research |  15 December 2015
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized TrialAnti-HCV Regimens in Noncirrhotic Patients With Genotype 1 Infection
Anita Kohli, MD; Sarah Kattakuzhy, MD; Sreetha Sidharthan, BS; et al.
Ann Intern Med. 2015;163(12):899-907. doi:10.7326/M15-0642
Original Research |  1 December 2015
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized TrialSofosbuvir With Velpatasvir for Treatment-Naive HCV-Infected Patients
Gregory T. Everson, MD; William J. Towner, MD; Mitchell N. Davis, DO; et al.
Ann Intern Med. 2015;163(11):818-826. doi:10.7326/M15-1000
Original Research |  1 December 2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized TrialSofosbuvir Plus Velpatasvir for Patients With HCV Infection
Stephen Pianko, MD, PhD; Steven L. Flamm, MD; Mitchell L. Shiffman, MD; et al.
Ann Intern Med. 2015;163(11):809-817. doi:10.7326/M15-1014
Original Research |  3 November 2015
Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods: A Cohort StudyIncident HBV Infection in MSM
Oluwaseun Falade-Nwulia, MD, MPH; Eric C. Seaberg, PhD; Anna E. Snider; et al.
Ann Intern Med. 2015;163(9):673-680. doi:10.7326/M15-0547
Original Research |  18 August 2015
Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System: A Case Series and Chart ReviewUnderascertainment of Acute HCV Infections
Shauna Onofrey, MPH; Jasneet Aneja, MPH; Gillian A. Haney, MPH; et al.
Ann Intern Med. 2015;163(4):254-261. doi:10.7326/M14-2939
Editorials |  18 August 2015
Celebrating the ACP Centennial: From the Annals Archive—Non-A, Non-B HepatitisCelebrating the ACP Centennial
Deborah Cotton, MD, MPH
Ann Intern Med. 2015;163(4):315. doi:10.7326/M15-1300
Ideas and Opinions |  4 August 2015
Hepatitis C Virus Treatment and Injection Drug Users: It Is Time to Separate Fact From FictionHCV Treatment and Injection Drug Users
Elinore F. McCance-Katz, MD, PhD; Ronald O. Valdiserri, MD, MPH
Ann Intern Med. 2015;163(3):224-225. doi:10.7326/M15-0007
Medicine and Public Issues |  4 August 2015 FREE
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United StatesMedicaid Restrictions of Sofosbuvir for Hepatitis C
Soumitri Barua; Robert Greenwald, JD; Jason Grebely, PhD; et al.
Ann Intern Med. 2015;163(3):215-223. doi:10.7326/M15-0406
Ideas and Opinions |  4 August 2015
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid ProgramsLimited Access to New HCV Treatment
Lauren A. Canary, MPH; R. Monina Klevens, DDS, MPH; Scott D. Holmberg, MD, MPH
Ann Intern Med. 2015;163(3):226-228. doi:10.7326/M15-0320
Original Research |  7 July 2015
Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized TrialC-EDGE Treatment-Naive Trial of Grazoprevir–Elbasvir
Stefan Zeuzem, MD; Reem Ghalib, MD; K. Rajender Reddy, MD; et al.
Ann Intern Med. 2015;163(1):1-13. doi:10.7326/M15-0785
Updates |  5 May 2015
Update in Gastroenterology and Hepatology: Evidence Published in 2014Update in Gastroenterology and Hepatology
John I. Allen, MD, MBA; David S. Weinberg, MD, MSc
Ann Intern Med. 2015;162(9):W96-W101. doi:10.7326/M15-0242
Original Research |  5 May 2015
The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 InfectionSofosbuvir-Based Regimens for Treatment of HCV Genotype 2 or 3 Infection
Benjamin P. Linas, MD, MPH; Devra M. Barter, MS; Jake R. Morgan, MS; et al.
Ann Intern Med. 2015;162(9):619-629. doi:10.7326/M14-1313
Editorials |  5 May 2015
A Cure for the High Cost of Hepatitis C Virus TreatmentA Cure for the High Cost of Hepatitis C Virus Treatment
Ohad Etzion, MD; Marc G. Ghany, MD, MHSc
Ann Intern Med. 2015;162(9):660-661. doi:10.7326/M15-0674
Original Research |  17 March 2015
Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United StatesCost-Effectiveness of HCV Treatment With Sofosbuvir and Ledipasvir
Jagpreet Chhatwal, PhD; Fasiha Kanwal, MD, MSHS; Mark S. Roberts, MD, MPP; et al.
Ann Intern Med. 2015;162(6):397-406. doi:10.7326/M14-1336
Original Research |  17 March 2015
Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C VirusCost-Effectiveness of New Regimens for Hepatitis C Virus
Mehdi Najafzadeh, PhD; Karin Andersson, MD; William H. Shrank, MD, MSHS; et al.
Ann Intern Med. 2015;162(6):407-419. doi:10.7326/M14-1152
Advertisement
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)